MA28550B1 - Composes et procedes permettant de traiter la dyslipidemie - Google Patents

Composes et procedes permettant de traiter la dyslipidemie

Info

Publication number
MA28550B1
MA28550B1 MA29410A MA29410A MA28550B1 MA 28550 B1 MA28550 B1 MA 28550B1 MA 29410 A MA29410 A MA 29410A MA 29410 A MA29410 A MA 29410A MA 28550 B1 MA28550 B1 MA 28550B1
Authority
MA
Morocco
Prior art keywords
methods
compounds
treating dyslipidemia
dyslipidemia
treating
Prior art date
Application number
MA29410A
Other languages
English (en)
Inventor
Michael Gregory Bell
Guoqing Cao
Ana Maria Escribano
Maria Carmen Fernandez
Peter Ambrose Lander
Nathan Bryan Mantlo
De La Nava Eva Maria Martin
Herranz Ana Isabel Mateo
Daniel Ray Mayhugh
Xiaodong Wang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA28550B1 publication Critical patent/MA28550B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
MA29410A 2004-03-26 2006-10-23 Composes et procedes permettant de traiter la dyslipidemie MA28550B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55713404P 2004-03-26 2004-03-26
US62116204P 2004-10-22 2004-10-22

Publications (1)

Publication Number Publication Date
MA28550B1 true MA28550B1 (fr) 2007-04-03

Family

ID=34963426

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29410A MA28550B1 (fr) 2004-03-26 2006-10-23 Composes et procedes permettant de traiter la dyslipidemie

Country Status (21)

Country Link
US (2) US7470705B2 (fr)
EP (2) EP1732933B1 (fr)
JP (1) JP2007530550A (fr)
KR (1) KR20070007112A (fr)
AT (2) ATE433984T1 (fr)
AU (1) AU2005230915A1 (fr)
BR (1) BRPI0508966A (fr)
CA (1) CA2557010A1 (fr)
CY (1) CY1110398T1 (fr)
DE (2) DE602005014955D1 (fr)
DK (1) DK1732933T3 (fr)
EA (1) EA200601785A1 (fr)
EC (1) ECSP066886A (fr)
ES (2) ES2326326T3 (fr)
IL (1) IL177962A0 (fr)
MA (1) MA28550B1 (fr)
NO (1) NO20064763L (fr)
PL (1) PL1732933T3 (fr)
PT (1) PT1732933E (fr)
SI (1) SI1732933T1 (fr)
WO (2) WO2005097805A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1670768T3 (pl) * 2003-10-08 2010-01-29 Lilly Co Eli Związki i sposoby leczenia dyslipidemii
EA200601785A1 (ru) * 2004-03-26 2007-02-27 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
MY139887A (en) 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
JP2008504266A (ja) 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
WO2006069162A1 (fr) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Nouveaux composes heterocycliques et leurs compositions pharmaceutiques
DK1848430T3 (da) 2004-12-31 2017-11-06 Dr Reddys Laboratories Ltd Nye benzylamin-derivativer som cetp-inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
JP4681526B2 (ja) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 医薬組成物
US7652023B2 (en) 2005-11-23 2010-01-26 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
AR069165A1 (es) 2007-11-05 2010-01-06 Novartis Ag Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia
PT2404901E (pt) 2007-12-03 2013-08-29 Novartis Ag Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como a hiperlipidemia ou a arteriosclerose
WO2009075857A2 (fr) * 2007-12-12 2009-06-18 Amgen Inc. Inhibiteurs du transporteur de glycine 1
WO2010110380A1 (fr) * 2009-03-27 2010-09-30 興和株式会社 Composé de pipéridine condensé et agent pharmaceutique le contenant
BRPI1010600A2 (pt) 2009-05-15 2016-03-15 Novartis Ag aril piridina como inibidores de aldosterona sintase
JP5654572B2 (ja) 2009-05-15 2015-01-14 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのベンズオキサゾロン誘導体
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
SG176010A1 (en) 2009-05-28 2011-12-29 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
ES2663351T3 (es) 2009-11-17 2018-04-12 Novartis Ag Derivados de aril-piridina como inhibidores de la aldosterona sintasa
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8575160B2 (en) 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
CN106478948B (zh) * 2010-02-24 2019-05-07 瑞立普萨公司 用作胆汁酸螯合剂的聚咪唑
DK2566505T3 (da) 2010-05-06 2020-01-20 Alphacore Pharma Llc Fremføring af kolesterylester til steroidogene væv
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
PL2729142T3 (pl) 2011-07-08 2018-10-31 Novartis Ag Sposób leczenia miażdżycy tętnic u osobników z wysokim poziomem triglicerydów
CA2845284C (fr) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Composes amines heterocycliques substitues comme inhibiteurs de la proteine de transfert d'ester cholesterylique (cetp)
JP6140168B2 (ja) 2011-09-27 2017-05-31 ドクター レディズ ラボラトリーズ リミテッド アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての５−ベンジルアミノメチル−６−アミノピラゾロ［３，４−ｂ］ピリジン誘導体
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
WO2013080999A1 (fr) 2011-11-29 2013-06-06 興和株式会社 Agent destiné à inhiber l'expression de l'arnm de npc1l1 et/ou de lipg et agent destiné à prévenir et/ou traiter l'obésité
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
NZ710574A (en) 2013-02-14 2017-11-24 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
US9266925B2 (en) 2013-07-25 2016-02-23 Novartis Ag Cyclic polypeptides for the treatment of heart failure
CA2972871A1 (fr) 2015-01-23 2016-07-28 Novartis Ag Conjugues d'acides gras de l'apeline synthetique presentant une demi-vie amelioree
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
US20240391941A1 (en) 2023-05-24 2024-11-28 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1515540A (en) 1975-12-16 1978-06-28 Labaz 4-amino-trans-decahydroquinoline derivatives
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
AU6279598A (en) * 1997-02-18 1998-09-08 Neurocrine Biosciences, Inc. Biazacyclic CRF antagonists
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
US7507753B2 (en) * 2001-12-28 2009-03-24 Takeda Chemical Industries Ltd. Biaryl compound and use thereof
PL371416A1 (en) 2002-02-01 2005-06-13 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
JP2003321472A (ja) * 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
ES2277142T3 (es) * 2002-08-30 2007-07-01 Japan Tobacco Inc. Compuesto de dibencilamina y su uso medicinal.
PL376156A1 (en) * 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
PL1670768T3 (pl) * 2003-10-08 2010-01-29 Lilly Co Eli Związki i sposoby leczenia dyslipidemii
EA200601785A1 (ru) * 2004-03-26 2007-02-27 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
MY139887A (en) 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法

Also Published As

Publication number Publication date
BRPI0508966A (pt) 2007-08-21
EP1732933B1 (fr) 2008-07-23
US7470705B2 (en) 2008-12-30
PT1732933E (pt) 2008-10-20
KR20070007112A (ko) 2007-01-12
SI1732933T1 (sl) 2008-10-31
EP1732933A1 (fr) 2006-12-20
ECSP066886A (es) 2006-11-24
WO2005097806A1 (fr) 2005-10-20
ES2308477T3 (es) 2008-12-01
EP1735320B1 (fr) 2009-06-17
ATE402180T1 (de) 2008-08-15
PL1732933T3 (pl) 2008-12-31
US20070173526A1 (en) 2007-07-26
DE602005008416D1 (de) 2008-09-04
DE602005014955D1 (de) 2009-07-30
EP1735320A1 (fr) 2006-12-27
CY1110398T1 (el) 2015-04-29
IL177962A0 (en) 2006-12-31
CA2557010A1 (fr) 2005-10-20
JP2007530550A (ja) 2007-11-01
EA200601785A1 (ru) 2007-02-27
WO2005097805A1 (fr) 2005-10-20
DK1732933T3 (da) 2008-10-27
ES2326326T3 (es) 2009-10-07
US20070208003A1 (en) 2007-09-06
AU2005230915A1 (en) 2005-10-20
NO20064763L (no) 2006-11-22
ATE433984T1 (de) 2009-07-15

Similar Documents

Publication Publication Date Title
CY1110398T1 (el) Ενωσεις για την αγωγη της δυσλιπιδαιμιας
ATE433447T1 (de) Pyrimiidinverbindungen
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
SE0302811D0 (sv) Novel compounds
TW200617009A (en) Organic compounds
TW200626579A (en) Inhibitors of the interaction between MDM2 and p53
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
ATE547415T1 (de) Inhibitoren der wechselwirkung zwischen mdm2 und p53
TW200640859A (en) Substituted bis aryl and heteroaryl compounds as selective 5HT2A antagonists
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
ATE422198T1 (de) Arylsulfonylnaphthalinderivate als 5ht2a- antagonisten
GEP20115201B (en) Cinnamoyl-piperazine derivatives and their use as par- i antagonists
JO2704B1 (en) Interference inhibition factors between MD2 and B53
SE0303541D0 (sv) New compounds
TW200510427A (en) Novel fused heterocycles and uses thereof
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
EA200801199A1 (ru) Ингибиторы киназы
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
TW200616977A (en) Enantiomers of selected fused heterocyclics and uses thereof
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
MA28268A1 (fr) Composes et techniques de traitement de la dyslipidemie
SE0303090D0 (sv) Novel compounds
TW200740781A (en) Novel compounds
NO20063293L (no) Farmasoytiske forbindelser
BRPI0615141A2 (pt) inibidores pentacìclicos de quinase